Table 4.

Summary of safety (safety population)

	Placebo (n = 32)	Tirasemtiv 250 mg (n = 32)	Tirasemtiv 500 mg (n = 32)
Patients with ≥1 treatment-emergent adverse event	13 (40.6)	12 (37.5)	21 (65.6)
Patients with a severe adverse event	0	0	1 (3.1)
Adverse events occurring in ≥2 patients
Dizziness	2 (6.3)	7 (21.9)	13 (40.6)
Headache	3 (9.4)	2 (6.3)	2 (6.3)
Dyspnea	0	1 (3.1)	2 (6.3)
Pollakiuria	1 (3.1)	0	3 (9.4)
Balance disorder	0	0	3 (9.4)
Feeling drunk	0	2 (6.3)	1 (3.1)
Anxiety	0	1 (3.1)	1 (3.1)
Blurred vision	0	1 (3.1)	2 (6.3)
Diarrhea	2 (6.3)	0	2 (6.3)
Dry mouth	1 (3.1)	0	1 (3.1)
Vomiting	1 (3.1)	0	1 (3.1)
Urinary tract infection	0	1 (3.1)	1 (3.1)
Muscle spasm	0	1 (3.1)	2 (6.3)

Values are given as n (%)